Prednisolon 20 mg JENAPHARM ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
41	巨細胞性動脈炎	1

41. 巨細胞性動脈炎

---

臨床試験数 : 131 /  薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-003978-13-IT (EUCTR)	02/07/2019	07/10/2020	A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis - na	Giant Cell Arteritis MedDRA version: 23.1;Level: PT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Prednisolon 1 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Trade Name: Prednisolon 1 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Trade Name: Prednisolon 5 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Trade Name: Prednisolon 20 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE Product Name: Upadacitinib Product Code: [ABT-494] INN or Proposed INN: Upadacitinib Trade Name: Prednisolon 10 mg JENAPHARM Product Name: Prednisolone Product Code: [na] INN or Proposed INN: PREDNISOLONE	ABBVIE DEUTSCHLAND GMBH & CO. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	420	Phase 3	United States;Portugal;Greece;Spain;Austria;Russian Federation;Italy;France;Hungary;Canada;Belgium;Australia;Denmark;Netherlands;Germany;Japan;New Zealand